This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Email citation

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2016 Jul 2;388(10039):3-4.

doi: 10.1016/S0140-6736(16)30311-7. Epub 2016 Apr 27.

Dupilumab: a potential new treatment for severe asthma

Kian Fan Chung¹

Affiliations

Affiliation

¹ Experimental Studies Unit, National Heart & Lung Institute, Imperial College London, UK; Biomedical Research Unit, Royal Brompton & Harefield NHS Trust, London SW3 6LY, UK. Electronic address: f.chung@imperial.ac.uk.

PMID: 27130690
DOI: 10.1016/S0140-6736(16)30311-7

Comment

Dupilumab: a potential new treatment for severe asthma

Kian Fan Chung. Lancet. 2016.

. 2016 Jul 2;388(10039):3-4.

doi: 10.1016/S0140-6736(16)30311-7. Epub 2016 Apr 27.

Author

Kian Fan Chung¹

Affiliation

¹ Experimental Studies Unit, National Heart & Lung Institute, Imperial College London, UK; Biomedical Research Unit, Royal Brompton & Harefield NHS Trust, London SW3 6LY, UK. Electronic address: f.chung@imperial.ac.uk.

PMID: 27130690
DOI: 10.1016/S0140-6736(16)30311-7

No abstract available

PubMed Disclaimer

Comment on

Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial.
Wenzel S, Castro M, Corren J, Maspero J, Wang L, Zhang B, Pirozzi G, Sutherland ER, Evans RR, Joish VN, Eckert L, Graham NM, Stahl N, Yancopoulos GD, Louis-Tisserand M, Teper A. Wenzel S, et al. Lancet. 2016 Jul 2;388(10039):31-44. doi: 10.1016/S0140-6736(16)30307-5. Epub 2016 Apr 27. Lancet. 2016. PMID: 27130691 Clinical Trial.

Similar articles

Dupilumab (Dupixent) for asthma.
[No authors listed] [No authors listed] Med Lett Drugs Ther. 2019 Jan 14;61(1563):6-8. Med Lett Drugs Ther. 2019. PMID: 30681662 No abstract available.
In response to dosing omalizumab in allergic asthma.
Jaffe JS, Massanari M. Jaffe JS, et al. J Allergy Clin Immunol. 2007 Jan;119(1):255-6. doi: 10.1016/j.jaci.2006.10.026. J Allergy Clin Immunol. 2007. PMID: 17208614 No abstract available.
Evaluating results of outcome studies of biological drugs.
Korenblat PE, Wedner HJ. Korenblat PE, et al. Lancet Respir Med. 2015 Sep;3(9):664-665. doi: 10.1016/S2213-2600(15)00276-3. Epub 2015 Jul 28. Lancet Respir Med. 2015. PMID: 26231287 No abstract available.
Omalizumab in the treatment of severe asthma: efficacy and current problems.
Pelaia G, Renda T, Romeo P, Busceti MT, Maselli R. Pelaia G, et al. Ther Adv Respir Dis. 2008 Dec;2(6):409-21. doi: 10.1177/1753465808100431. Ther Adv Respir Dis. 2008. PMID: 19124386 Review.
Monoclonal antibodies for chronic refractory asthma and pipeline developments.
Polosa R, Casale T. Polosa R, et al. Drug Discov Today. 2012 Jun;17(11-12):591-9. doi: 10.1016/j.drudis.2012.01.012. Epub 2012 Jan 25. Drug Discov Today. 2012. PMID: 22306350 Review.

See all similar articles

Cited by

The emerging roles of eosinophils: Implications for the targeted treatment of eosinophilic-associated inflammatory conditions.
Lombardi C, Berti A, Cottini M. Lombardi C, et al. Curr Res Immunol. 2022 Mar 21;3:42-53. doi: 10.1016/j.crimmu.2022.03.002. eCollection 2022. Curr Res Immunol. 2022. PMID: 35496822 Free PMC article. Review.
AllergoOncology: Danger signals in allergology and oncology: A European Academy of Allergy and Clinical Immunology (EAACI) Position Paper.
Bergmann C, Poli A, Agache I, Bianchini R, Bax HJ, Castells M, Crescioli S, Dombrowicz D, Ferastraoaru D, Fiebiger E, Gould HJ, Hartmann K, Izquierdo E, Jordakieva G, Josephs DH, Jutel M, Levi-Schaffer F, de Las Vecillas L, Lotze MT, Osborn G, Pascal M, Redegeld F, Rosenstreich D, Roth-Walter F, Schmidt-Weber C, Shamji M, Steveling EH, Turner MC, Untersmayr E, Jensen-Jarolim E, Karagiannis SN. Bergmann C, et al. Allergy. 2022 Sep;77(9):2594-2617. doi: 10.1111/all.15255. Epub 2022 Mar 14. Allergy. 2022. PMID: 35152450 Free PMC article.
The multifaceted roles of FOXM1 in pulmonary disease.
Li Y, Wu F, Tan Q, Guo M, Ma P, Wang X, Zhang S, Xu J, Luo P, Jin Y. Li Y, et al. Cell Commun Signal. 2019 Apr 16;17(1):35. doi: 10.1186/s12964-019-0347-1. Cell Commun Signal. 2019. PMID: 30992007 Free PMC article. Review.
Innovative Therapies for Severe Asthma.
Christensen MA, Ott M. Christensen MA, et al. Fed Pract. 2017 Dec;34(12):25-31. Fed Pract. 2017. PMID: 30766246 Free PMC article. Review.
Current State and Future of Biologic Therapies in the Treatment of Asthma in Children.
Abrams EM, Becker AB, Szefler SJ. Abrams EM, et al. Pediatr Allergy Immunol Pulmonol. 2018 Sep 1;31(3):119-131. doi: 10.1089/ped.2018.0901. Epub 2018 Sep 17. Pediatr Allergy Immunol Pulmonol. 2018. PMID: 30283711 Free PMC article. Review.

See all "Cited by" articles

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Other Literature Sources
- The Lens - Patent Citations Database
- scite Smart Citations
Medical
- MedlinePlus Consumer Health Information
- MedlinePlus Health Information